Literature DB >> 23974964

Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France.

Hassan Serrier1, Hélène Sultan-Taieb, Danièle Luce, Sophie Bejean.   

Abstract

PURPOSE: The objective of this article was to estimate the social cost of respiratory cancer cases attributable to occupational risk factors in France in 2010.
METHODS: According to the attributable fraction method and based on available epidemiological data from the literature, we estimated the number of respiratory cancer cases due to each identified risk factor. We used the cost-of-illness method with a prevalence-based approach. We took into account the direct and indirect costs. We estimated the cost of production losses due to morbidity (absenteeism and presenteeism) and mortality costs (years of production losses) in the market and nonmarket spheres.
RESULTS: The social cost of lung, larynx, sinonasal and mesothelioma cancer caused by exposure to asbestos, chromium, diesel engine exhaust, paint, crystalline silica, wood and leather dust in France in 2010 were estimated at between 917 and 2,181 million euros. Between 795 and 2,011 million euros (87-92%) of total costs were due to lung cancer alone. Asbestos was by far the risk factor representing the greatest cost to French society in 2010 at between 531 and 1,538 million euros (58-71%), ahead of diesel engine exhaust, representing an estimated social cost of between 233 and 336 million euros, and crystalline silica (119-229 million euros). Indirect costs represented about 66% of total costs.
CONCLUSION: Our assessment shows the magnitude of the economic impact of occupational respiratory cancers. It allows comparisons between countries and provides valuable information for policy-makers responsible for defining public health priorities.

Entities:  

Mesh:

Year:  2013        PMID: 23974964     DOI: 10.1007/s10198-013-0528-6

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  50 in total

1.  [A study based on national DRG data to evaluate work load and practice relating to cancer patients in not-for-profit hospitals].

Authors:  L Borella; P Peuvrel; M Sauvage; D Maraninchi; T Philip
Journal:  Rev Epidemiol Sante Publique       Date:  2000-01       Impact factor: 1.019

2.  Modeling the economic burden of diseases imputable to stress at work.

Authors:  Sophie Béjean; Hélène Sultan-Taïeb
Journal:  Eur J Health Econ       Date:  2005-03

3.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

4.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

5.  The global burden of selected occupational diseases and injury risks: Methodology and summary.

Authors:  Deborah Imel Nelson; Marisol Concha-Barrientos; Timothy Driscoll; Kyle Steenland; Marilyn Fingerhut; Laura Punnett; Annette Prüss-Ustün; James Leigh; Carlos Corvalan
Journal:  Am J Ind Med       Date:  2005-12       Impact factor: 2.214

6.  Occupational disease and workers' compensation: coverage, costs, and consequences.

Authors:  J Paul Leigh; John A Robbins
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

7.  What percentage of workers with work-related illnesses receive workers' compensation benefits?

Authors:  J Biddle; K Roberts; K D Rosenman; E M Welch
Journal:  J Occup Environ Med       Date:  1998-04       Impact factor: 2.162

8.  Pooled reanalysis of cancer mortality among five cohorts of workers in wood-related industries.

Authors:  P A Demers; P Boffetta; M Kogevinas; A Blair; B A Miller; C F Robinson; R J Roscoe; P D Winter; D Colin; E Matos
Journal:  Scand J Work Environ Health       Date:  1995-06       Impact factor: 5.024

9.  Estimating the cost of illness.

Authors:  D P Rice
Journal:  Am J Public Health Nations Health       Date:  1967-03

10.  [Volume and costs of the hospital management of cancer in France in 1999].

Authors:  Laurent Borella; Stéphane Finkel; Nicolas Crapeau; Patrick Peuvrel; Martine Sauvage; Lionel Perrier; Eric Lepage; Jean Villeminot; Bernard Garrigues
Journal:  Bull Cancer       Date:  2002-09       Impact factor: 1.276

View more
  6 in total

1.  Response to the letter to the editor by Latza et al.: Indirect evaluation of attributable fractions for psychosocial work exposures: a difficult research area.

Authors:  Isabelle Niedhammer; Hélène Sultan-Taïeb; Jean-François Chastang; Greet Vermeylen; Agnès Parent-Thirion
Journal:  Int Arch Occup Environ Health       Date:  2013-11-28       Impact factor: 3.015

Review 2.  Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Authors:  Jamison Pike; Scott D Grosse
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

Review 3.  The economic burden of head and neck cancer: a systematic literature review.

Authors:  Erika Wissinger; Ingolf Griebsch; Juliane Lungershausen; Talia Foster; Chris L Pashos
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

4.  Costs of productivity loss due to occupational cancer in Canada: estimation using claims data from Workers' Compensation Boards.

Authors:  W Dominika Wranik; Adam Muir; Min Hu
Journal:  Health Econ Rev       Date:  2017-02-10

5.  Medical costs of asbestos-related diseases in Spain between 2004 and 2011.

Authors:  Montserrat García-Gómez; Rosa Urbanos Garrido; Rosario Castañeda López; Alfredo Menéndez-Navarro
Journal:  Ind Health       Date:  2016-06-23       Impact factor: 2.179

6.  Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.

Authors:  Christos Chouaid; Jean Baptiste Assié; Pascal Andujar; Cecile Blein; Charlène Tournier; Alexandre Vainchtock; Arnaud Scherpereel; Isabelle Monnet; Jean Claude Pairon
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.